Pre-treatment with GLP-1(7–36)amide in patients with ischemic heart disease caused by balloon occlusion protected against LV systolic and diastolic dysfunction and improved the recovery of LV performance during reperfusion, without detectable changes in cardiac glucose metabolism, suggesting an independent mechanism for GLP-1 not related to glucose metabolic effects [174]. Here, GCG is linked to coronary artery disorder.